Illumina launched BioInsight, a business unit offering to run and retain ownership of large, costly sequencing projects for pharma customers and to develop packaged datasets and analytic tools. CEO Jacob Thaysen framed the move as shifting Illumina from pure reagent supplier to a data and algorithm company that can accelerate pharma R&D while monetizing high‑value genomic datasets. The plan includes exclusive development windows for partners and eventual broader licensing of curated datasets for AI model training. The shift signals growing commercialization of sequencing‑generated data and an industry tilt toward data assets and integrated analytics alongside traditional instrument and reagent sales.